CD274 and neoplasm: Phase I trials of several PD-1 receptor monoclonal antibodies, including nivolumab (32), MK-3475 (33), as well as the PD-L1 antibody MPDL-3280A (34) have all shown evidence of anti-tumor activity in heavily treated NSCLC patients.